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Abstract
Objective: To study the transfer of parenteral iron
sucrose into maternal milk in the postpartum period.
Study design: Ten healthy lactating mothers with func-
tional iron deficiency 2–3 days after delivery received
100 mg intravenous iron sucrose and were observed
together with a control group (ns5) without iron treat-
ment during four days. Milk samples were taken before
the treatment and every day afterwards.
Results: Mean milk iron levels at baseline were 0.43 and
0.46 mg/kg in the treatment and control group and
decreased until the end of observation in both groups by
0.11 mg/kg. No significant difference between the groups
was found on any study day as well as in the mean
change from baseline over all four days.
Conclusion: We could not show transfer of iron-suco-
rose into maternal milk for the given dosage. Since par-
enteral iron sucrose is widely used in obstetrics, the
results provide information about safety of parenteral iron
sucrose in the lactation period. The findings are also in
agreement with other reports on active biological mam-
mary gland regulation of milk iron concentration.
Keywords: Iron content; iron sucrose; lactation; milk;
mother; postpartum.
Introduction
Postpartum iron deficiency, with or without anemia, is a
frequent problem, which may be treated with intravenous
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iron supplements. As this route of administration leads
to temporary high serum iron levels, concern exists about
the amount of iron that reaches the breast-fed infants.
This is important, because iron overload could increase
the risk of bacterial gastro-intestinal infection for the
infant w4x. Intravenous iron sucrose complex is increas-
ingly used in the peripartum period w1–3, 8, 11, 12x, how-
ever, no definite correlation between serum iron levels
and milk iron concentrations was observed, because the
assumption is that milk iron content is rather independent
from circulating iron w5x. However, clinical data on milk
iron levels after intravenous iron administration are not
available.
Hence, a study on iron transfer into the mother’s milk
was required or, equivalently, a proof of low iron content
in breast milk after intravenous iron treatment. The study
aimed to show no relevant increase in milk iron levels as
compared to pretreatment values.
Because milk produced after delivery is known to show
decreasing iron concentrations over time w13x, the inves-
tigation considered a control group in a parallel group
study design for clear interpretation of the measurements
after iron administration. If elevated iron concentrations
after intravenous supplementation were found, additional
determination of lactoferrin bound iron in the milk was
planned, since lactoferrin helps prevent iron overload in
the infant by its iron binding capacity w4x.
Patients and methods
The study plan included 15 lactating mothers with functional iron
deficiency (transferrin saturation -15%) and mild anemia
(hemoglobin 10–12 g/dL), but otherwise normal laboratory val-
ues, absence of infection and malignancy, and no history of
intravenous iron supplementation within the last three weeks.
Sufficient milk and a healthy infant was a further prerequisite
as well as written informed consent for study participation. In
ten patients a single dose of 100 mg intravenous iron sucrose
(iron(III)-hydroxide sucrose complex; trade name Venofer (Vifor
International Inc., St. Gallen, Switzerland) was administered on
day 0 of the study. The other five patients served as controls
and did not receive any iron preparation. Laboratory examina-
tions were done on day 0 prior to iron administration and there-
after every day until day 4. Milk samples of 5–10 mL were
collected directly after breast-feeding at between 08:00 and
18:00 h. The samples were frozen at –188 and sent for analysis
for milk iron concentrations to an experienced laboratory using
atomic absorption spectroscopy by ICP-OES instrument OPTI-
MA 3000 (Perkin Elmer Instruments, Norwalk, CT). The intended
second step of determining the lactoferrin bound iron was
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Table 1 Patients’ characteristics and hematology at study entry.
Parameter Iron sucrose Control group Group
Mean (SD) Mean (SD) comparison*
Age (years) 32.8 (6.0) 30.0 (4.4) n.s.
Body weight (kg) 72.3 (4.4) 68.4 (7.1) n.s.
Hemoglobin (g/dL) 11.0 (0.45) 11.7 (0.90) n.s.
RBC count (1012/L) 3.79 (0.37) 3.83 (0.50) n.s.
Serum iron (mmol/L) 9.77 (4.7) 10.9 (4.9) n.s.
Transferrin (mmol/L) 39.7 (8.1) 41.0 (12.0) n.s.
Transferrin saturation (%) 11.9 (4.7) 12.9 (3.0) n.s.
*t-test; RBC and transferrin by Mann-Whitney U-test. n.s.; not significant (P)0.05).
Table 2 Milk iron content (mg/kg) on start day 0 and change from baseline during follow-up.
Time course Iron sucrose Control group Median Significance*
Mean (SD) Mean (SD) differencen P-value
Day 0 (baseline) 0.43 (0.10) 0.46 (0.11) – –**
Day 1 (change) y0.07 (0.11) q0.04 (0.22) y0.04 0.84
Day 2 (change) y0.10 (0.12) y0.11 (0.13) q0.01 0.43
Day 3 (change) y0.11 (0.14) y0.16 (0.19) q0.05 0.34
Day 4 (change) y0.11 (0.18) y0.11 (0.12) y0.04 0.67
Mean change, day 1–4 y0.096 (0.12) y0.085 (0.11) y0.026 0.66
*Mann-Whitney U-test (one-sided); **comparison at baseline: Ps0.86 (two-sided).
nneg./pos. sign means iron sucrose showed lower/higher values than control group.
dropped, since total iron examinations showed low values dur-
ing the follow-up days in all of the 15 subjects.
Statistical analysis
Mean values of the double readings of iron concentrations in
milk were used. Due to some skewness of the data, group com-
parisons were done by Wilcoxon-Mann-Whitney test (Mann-
Whitney U-test). Because the study investigated only the
question of a possible increase of iron content in the treatment
group, one-sided tests with more statistical power were per-
formed. Other parameters were compared between study
groups either by t-test or by Wilcoxon-Mann-Whitney test, as
appropriate (two-sided). Significance threshold was defined by
as0.05 (PF0.05). Primary parameter of the study consisted of
the milk iron concentrations after day 0.
Results
Demographic data
Mean age of the mothers in the treatment and control
group was 32.8 and 30.0 years. Measurements of body
weight showed 72.3 and 68.4 kg on average (Table 1).
Hematological values
Mean hemoglobin values of 11.0 and 11.7 g/dL at study
start indicated subnormal findings. Functional iron defi-
ciency was documented by transferrin saturation of
-15% (means of 11.9% and 12.9%, respectively)
and was accompanied by serum iron of 9.8 and 10.9
mmol/L on average. Group differences were not signifi-
cant (Table 1).
Treatment and follow-up documentation
Of the 15 mothers included in the study on day 0, 10
were given the full dose of 100 mg intravenous iron
sucrose. The 4-day observation period started in both
study groups 2–3 day after the child was born, after
secretion of colostrum had begun. No other iron prepa-
rations were taken at any time during the study.
Patients’ adherence to the study protocol was given
as complete milk samples collected from each of the 15
participants until the end of the regular study.
Milk iron concentrations
Milk iron content at baseline was similar in both study
groups. Mean concentrations of 0.43 and 0.46 mg/kg
found in the treatment and control group were not sig-
nificantly differerent (Table 2). The 4-day observation peri-
od showed decreasing mean iron concentrations in both
study groups (Figure 1). Only on the first post-treatment
day some increase occurred in the control group due to
a single elevated measurement. Mean decrease after four
days reached about 0.11 mg/kg in both groups and
mean change from baseline over all four days was again
very similar in treated and untreated patients. According-
ly, no statistically significant intergroup difference was
observed on any day or in regard to the averaged mean
decrease of all four days (Table 2).
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Figure 1 Milk iron content before and after administration of
100 mg intravenous iron on day 0 (mean"SD).
Due to the small samples of the study, power analysis
was done in order to determine which minimal true group
difference would result in statistical significance. Taking
the SD values of the mean change parameter of all four
days on Table 2, it resulted for the study groups with 10
and 5 patients with a power of 80% to detect a difference
of 0.165 mg/kg at the 5% significance level (PF0.05;
one-sided t-test).
This means non-significance does not exclude a pos-
sible group difference of up to about 0.17 mg/kg but a
larger difference is likely to be detected as statistically
significant.
Discussion
Iron determinations in breast milk before and after a
100 mg IV dose of iron sucrose showed mean values of
about 0.30–0.45 mg/kg, being in the lower range of
known early postpartum milk iron levels. These levels
were reported with numerous variations depending on
the time after delivery, how milk samples were collected
(sample volume and daytime), and possible population
influences w6, 7, 9, 13x. At the beginning of the study,
2–3 days after delivery, treatment and control group were
comparable in regard to functional iron deficiency para-
meters in blood and baseline milk iron levels, which
decreased during the 4-day follow-up in a similar way in
both groups by about 0.11 mg/kg. Corresponding to the
follow-up with a similarity of the groups, no statistical
significant differences were found on any of the four days
or regarding the mean value of all four days.
Although the similar course of the two study groups
may lead to the assumption of no group difference and
hence no suspicion of possibly higher iron values in the
treatment group, the study result may nevertheless have
occurred by chance if the samples considered were too
small. Therefore power analysis was performed, which
indicated that for the sample sizes chosen, the detecta-
ble difference was about 0.17 mg/kg. This means that
the true population values might be higher than observed
by that extent. However, these iron contents would again
represent low findings, since they would still lie within the
range of values reported from subjects without postpar-
tum iron treatment or from non-anemic, healthy mothers
w7, 9, 14, 15x.
The result of decreasing milk iron levels after the
100 mg intravenous iron dose may be intriguing, how-
ever, postpartum milk iron content is known to decrease
in healthy untreated subjects w13x. Another critique might
relate to the first sample after the iron treatment taken
only on the next day. A missed increase of milk iron con-
tent immediately after iron injection may indeed be a valid
consideration. One must, however, also question if such
short and transient elevation could be harmful for the
infant when the subsequent feeding days contain normal
values. We think rather not. In addition, the following fact
supports the notion that milk iron content is probably not
elevated during the first hours after an intravenous iron
injection. No significant correlation between milk iron and
iron status parameters of the mother, or intake of oral iron
supplements, was found in various reports on postpar-
tum milk iron contents w15x. Moreover, serum iron on day
0 before administration of iron sucrose was not signifi-
cantly correlated with milk iron concentrations, although
some dependency may not be excluded. Due to those
observations, an active biological regulation of iron
uptake by mammary glands is strongly supposed w10,
15x, because it explains the laboratory findings in the
milk. The results of our investigation also support this
assumption.
In conclusion, in this study postpartum administration
of 100 mg intravenous iron sucrose did not lead to
enhanced iron contents of the colostrum during the fol-
lowing days but shows levels in the range of untreated
healthy mothers. The findings are in agreement with other
reports on postpartum subjects with or without oral iron
supplementation leading to the assumption of a regula-
tion of milk iron concentrations by active mammary gland
mechanisms, by which breast-fed infants are protected
from iron overload.
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